Phototherapy and photochemotherapy for polymorphic light eruption desensitisation: a five year case series review from a university teaching hospital

TY - JOUR

T1 - Phototherapy and photochemotherapy for polymorphic light eruption desensitisation

T2 - a five year case series review from a university teaching hospital

AU - Aslam, A.

AU - Fullerton, L.

AU - Ibbotson, S. H.

N1 - no funding info

PY - 2017/5/11

Y1 - 2017/5/11

N2 - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

AB - Polymorphic light eruption (PLE) is the most common immunological photodermatosis, with a prevalence of 18% in Europe1. The pathogenesis of PLE appears to involve delayed cell mediated hypersensitivity and aberrant Langerhans cell function2,3. Phototherapy, using narrowband UVB (UVB) or psoralen-ultraviolet A (PUVA) photochemotherapy, is widely used for prophylactic desensitisation in PLE, with benefit experienced in 90% of patients4,5

KW - Phototherapy

KW - Polymorphic light eruption

KW - Desensitisation

KW - UVB

U2 - 10.1111/phpp.12310

DO - 10.1111/phpp.12310

M3 - Letter

C2 - 28419574

SN - 0905-4383

VL - 33

SP - 225

EP - 227

JO - Photodermatology, Photoimmunology & Photomedicine

JF - Photodermatology, Photoimmunology & Photomedicine

IS - 4

ER -